<DOC>
	<DOC>NCT00379483</DOC>
	<brief_summary>A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was conducted to investigate the efficacy and safety of deferasirox in patients aged â‰¥ 18 years with transfusion-dependent iron overload. The objective of this extension study is to assess the long-term safety of deferasirox and to provide treatment in patients with transfusional iron overload.</brief_summary>
	<brief_title>Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients with transfusional iron overload who have successfully completed the one year chelation treatment in the deferasirox trial or the foodeffect substudy and who were considered by the investigator eligible to continue chelation therapy with deferasirox Pregnant or breast feeding patients Patients being considered by the investigator potentially unreliable and/or a history of noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Transfusional iron overload</keyword>
	<keyword>Deferasirox</keyword>
</DOC>